Joint (NASDAQ:JYNT - Get Free Report) announced its quarterly earnings data on Thursday. The company reported $0.06 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.06, Zacks reports. Joint had a positive return on equity of 8.24% and a negative net margin of 13.95%.
Joint Trading Up 0.2 %
JYNT traded up $0.02 during trading hours on Thursday, hitting $10.54. The company's stock had a trading volume of 65,482 shares, compared to its average volume of 36,736. The business's 50-day moving average price is $11.07 and its 200-day moving average price is $11.16. Joint has a 12 month low of $9.58 and a 12 month high of $17.82. The stock has a market cap of $157.93 million, a price-to-earnings ratio of -9.25 and a beta of 1.61.
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded shares of Joint from a "hold" rating to a "buy" rating in a research report on Friday, November 15th.
View Our Latest Analysis on Joint
About Joint
(
Get Free Report)
The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Joint, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Joint wasn't on the list.
While Joint currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
